Skip to main content

CURAM (Sandoz Pty Ltd)

Product name
CURAM
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
159 working days (255)
Active ingredients
amoxicillin sodium; potassium clavulanate
Registration type
New generic medicine
Indication

CURAM (powder for injection) is indicated for the short term treatment of serious bacterial infections such as:

  • Upper Respiratory Tract Infections (including ENT): e.g. mastoiditis, tonsillitis, otitis media, epiglottitis and sinusitis when accompanied by severe signs and symptoms
  • Lower Respiratory Tract Infections: e.g. acute exacerbations of chronic bronchitis, lobar, broncho-pneumonia and community acquired pneumonia
  • Genito-urinary Tract Infections: e.g. cystitis, urethritis, pyelonephritis, female genital infections
  • Gastrointestinal infections: e.g. intra-abdominal sepsis, peritonitis
  • Skin and skin structure infections, in particular cellulitis, animal bites, diabetic foot infections, vascular surgery infection/ischaemic soft tissue infection, severe dental abscess
  • Other Infections e.g. septic abortion, puerperal sepsis, post-surgical infections
  • Curam is indicated for prophylaxis against infection in major surgical procedures that may be associated with higher risk of infectious complications e.g. gastrointestinal surgery.

Help us improve the Therapeutic Goods Administration site